Fibrocor: Advancing Fibrosis Therapies from the Berkshires | BIC Stage 2 Accelerator Showcase скачать в хорошем качестве

Fibrocor: Advancing Fibrosis Therapies from the Berkshires | BIC Stage 2 Accelerator Showcase

Fibrocor is a near-clinical-stage biotechnology company developing therapies for kidney and lung fibrosis. At the BIC Stage 2 Accelerator Showcase, CEO Bill Newsome shared how his global team—spanning Canada, Belgium, and the U.S.—is advancing treatments for high-need conditions like Alport syndrome and idiopathic pulmonary fibrosis. Bill, a Berkshire native, returned to the region to build Fibrocor’s U.S. operations and found a vital support system at the Berkshire Innovation Center—connecting with executive mentors, biotech leaders, and a community of fellow entrepreneurs. 🏥 Key Highlights: 3 fibrosis programs nearing clinical trials Merging with an Australian biotech to raise a $40M Series A Global R&D with U.S. leadership based in the Berkshires Strategic biotech connections formed via the BIC network Support in story development, leadership coaching, and communications 🎤 “Being able to sit in a room with like-minded entrepreneurs doing very different things... really opened my mind.” 📍 Filmed live at the Berkshire Innovation Center during the 2025 S2A Showcase. — 🚀 Now Accepting Applications for the BIC Stage 2 Accelerator Hard tech and mission-driven founders. 📝 No fees. No equity taken. 🔗 https://www.berkshireinnovationcenter... 📧 Submit to: [email protected] — #Fibrocor #Biotech #LifeSciences #FibrosisResearch #AlportSyndrome #PulmonaryFibrosis #RareDisease #ClinicalTrials #BerkshireInnovationCenter #BICAccelerator #Stage2Accelerator #WesternMass #BioPharma #HealthTech